## Amendments to the Claims

4, H\* 4

- 1. (Original) A preventive or therapeutic agent for asthma, comprising HGF or a salt thereof as an active ingredient.
- **2.** (Original) The preventive or therapeutic agent for asthma according to claim 1, wherein HGF is a peptide comprising an amino acid sequence represented by SEQ ID NO: 1 or 2, a peptide comprising an amino acid sequence substantially identical to an amino acid sequence represented by SEQ ID NO: 1 or 2, or a partial peptide thereof.
- **3. (Original)** A preventive or therapeutic agent for asthma, comprising a DNA encoding HGF as an active ingredient.
- **4. (Original)** The preventive or therapeutic agent for asthma according to claim 3, wherein the DNA encoding HGF is a DNA comprising a base sequence represented by SEQ ID NO: 3 or 4, or a base sequence which hybridizes with a base sequence represented by SEQ ID NO: 3 or 4 under highly stringent conditions.
- **5.** (Currently amended) The preventive or therapeutic agent for asthma according to claim 3-or 4, wherein the DNA encoding HGF is inserted into a recombinant expression vector.
- **6. (Original)** The preventive or therapeutic agent for asthma according to claim 5, wherein the recombinant expression vector is adeno-associated virus (AAV), adenovirus, retrovirus, poxvirus, herpesvirus, herpes simplex virus, lentivirus (HIV), sendaivirus, Epstein-Barr virus (EBV), vaccinia virus, poliovirus, sindbis virus, SV40, pCAGGS, pBK-CMV, pcDNA3.1 or pZeoSV.
- 7. (Currently amended) The preventive or therapeutic agent for asthma according to claim 5-or-6, wherein the recombinant expression vector is further contained in a host cell.

**8.** (Currently amended) The preventive or therapeutic agent for asthma according to any one of claims 3 to 7 claim 3, wherein the DNA encoding HGF, or the recombinant expression vector containing the DNA encoding HGF is contained in a liposome or a microcapsule.

(4)

1631 Ale 4

- 9. (Currently amended) The preventive or therapeutic agent for asthma according to any one of claims 1 to 8 claim 1, further comprising a pharmaceutically acceptable carrier.
- 10. (Original) A method for preventing or treating asthma, comprising suppressing airway inflammation by administering an effective amount of HGF or a salt thereof to a mammal.
- 11. (Original) A method for preventing or treating asthma, comprising suppressing airway inflammation by administering an effective amount of a DNA encoding HGF to a mammal.
- 12. (Currently amended) Use of HGF or a salt thereof A method for preparing a preventive or therapeutic agent for asthma, which comprises suppressing airway inflammation. mixing HGF or a salt thereof with a pharmaceutically acceptable carrier.
- 13. (Currently amended) Use of a DNA encoding HGF A method for preparing a preventive or therapeutic agent for asthma, which comprises suppressing airway inflammation inserting a DNA encoding HGF into a recombinant expression vector.